IMS Retail Drug Monitor

Transcription

1 IMS Retail Drug Monitor Tracking 13 Key Global Pharma Markets 12 months to November 2004 Regional Sales Breakdown: $US Billions % 180 Value US$Bill 160 % Growth IMS HEALTH, the global healthcare information company, today reported a 7% growth in drug sales through retail pharmacies in 13 key markets in the 12- month period from December 2003 through to November 2004, closing at US$345 billion % IMS Retail Drug Monitor covers direct and indirect pharmacy channel purchases from wholesalers and manufacturers in 13 key countries. Sales figures are at ex-manufacturer prices and include all prescription and certain over-the-counter data. Figures include sales from the hospital sector in Japan and mail order in the USA. North America Europe Japan Retail pharmacy sales for these key markets had a 7% growth at constant exchange to November 2004, the same as our previous survey. Source: IMS Health Sales in the top five European markets showed a 6% constant exchange growth. Therapy Sales Breakdown: $US Millions 80,000 70,000 60,000 50,000 40,000 30,000 20,000 10,000 67,894 64,283 49,260 29,885 27,784 North America posted an 8% sales growth at $183 billion in sales in the 12 months to November. The Key therapy growth areas for North America are the Central Nervous System and Cardiovascular groups with a 12% growth at constant exchange, a slight decrease to last months survey. Japan s overall growth at constant exchange increased slightly to 2%, with a market worth $56.75 billion in the 12 months to November US dollar Growth in the three Latin American Markets remained the same as our last survey. 0 CARDIOVASCULAR ALIMENTARY ANTI-INFECTIVES CNS RESPIRATORY Source: IMS Health By therapeutic category the biggest increase worldwide remains the blood agents category, with a sales growth at constant exchange of 13%. The single largest therapeutic sub category in dollar sales continues to be the C10, hypolipidemia, class selling $26.24 billion with a growth of 12.2% in the 12 months to November 2004, a slight decrease from our last survey. The second biggest group is the A2, anti-ulcerants, class at $21.85 billion and a 1% growth. Press Contact/Editor: Gail Nielen Marketing Communications, IMS Health 7, Harewood Avenue, London NW1 6JB, UK. T: F: gnielen@uk.imshealth.com The best selling drug for the 12 months ending November 2004 was still Lipitor, worth over $10.43 billion, with growth at 13.3%. Plavix still has the largest growth at the top with 32.5%, a slight decrease since our last survey. The five top drugs are 1. Lipitor, 2. Zocor, 3. Nexium, 4. Norvasc, 5. Plavix. The top 5 corporations in the year to November 2004 in order continued to be: 1: Pfizer, 2. GlaxoSmithKline, 3. Merck, 4. AstraZeneca, 5, Novartis.

2 12 MONTHS 12 MONTHS % GROWTH NOV 2004 NOV 2003 % GROWTH AT CONSTANT US$ MILLIONS US$ MILLIONS US$ EXCHANGE* SELECTED WORLD 345, , NORTH AMERICA 183, , U.S.A. 173, , CANADA 9,949 8, EUROPE (leading 5) 86,115 73, GERMANY 25,092 21, FRANCE 21,035 17, ITALY 14,409 12, UNITED KINGDOM 15,429 12, SPAIN 10,149 8, JAPAN (*including Hospital) 56,758 51, LATIN AMERICA (leading 3) 13,179 11, MEXICO 6,441 6, BRAZIL 4,954 4, ARGENTINA 1,784 1, AUSTRALIA/NEW ZEALAND 5,229 4, THERAPEUTIC CATEGORY 1 CARDIOVASCULAR 67,894 60, CENTRAL NERVOUS SYSTEM 64,283 56, ALIMENTARY/METABOLISM 49,260 45, RESPIRATORY 29,885 27, ANTI-INFECTIVES 27,784 26, MUSCULO-SKELETAL 22,472 19, GENITO-URINARY 18,469 17, CYTOSTATICS 16,959 14, DERMATOLOGICALS 10,101 9, BLOOD AGENTS 12,515 10, SENSORY ORGANS 6,977 6, DIAGNOSTIC AGENTS 6,327 5, HORMONES 5,540 4, MISCELLANEOUS 4,089 3,956 3 (1) 15 HOSPITAL SOLUTIONS 1,999 1,887 6 (2) 16 PARASITOLOGY *Constant Exchange takes out the effect of fluctuating exchange rates

3 US JAPAN GERMANY FRANCE ITALY UK $M + $M + $M + $M + $M + $M + TOTAL 173, , , , , ,429 8 CARDIOVASCULAR 31, , ,096 (4) 4, , ,908 8 CENTRAL NERVOUS SYST 40, , , , , , ALIMENTARY/MET. 23, , , , , ,252 5 ANTI-INFECTIVES 13, ,981 (2) 1, , ,242 (6) RESPIRATORY 15, ,768 (4) 1, , , ,770 7 MUSCULO-SKELETAL 11, , , , GENITO-URINARY 10, , ,333 (2) 1,165 (2) CYTOSTATICS 6, , , , DERMATOLOGICALS 4, , (6) (1) BLOOD AGENTS 4, , , SENSORY ORGANS 2, , DIAGNOSTIC AGENTS 2, , HORMONES 2, ,120 (2) (5) MISCELLANEOUS 1,421 (13) 1, HOSPITAL SOLUTIONS ,814 (3) PARASITOLOGY CANADA SPAIN BRAZIL MEXICO ARGENTINA AUST./NZ $M + $M + $M + $M + $M + $M + TOTAL 9, , , , , , CARDIOVASCULAR 2, , , CENTRAL NERVOUS SYST 1, , ALIMENTARY/MET. 1, , , ANTI-INFECTIVES (5) RESPIRATORY , MUSCULO-SKELETAL GENITO-URINARY CYTOSTATICS (26) (45) DERMATOLOGICALS BLOOD AGENTS SENSORY ORGANS (1) DIAGNOSTIC AGENTS (15) (3) HORMONES MISCELLANEOUS 95 (2) HOSPITAL SOLUTIONS 2 (17) (3) 2 13 PARASITOLOGY : Growth is at Constant Exchange

4 NORTH AMERICA EUROPE TOP FIVE JAPAN $M % + $M % + $M % + CARDIOVASCULAR 33, , , CENTRAL NERVOUS SYSTEM 42, , , ALIMENTARY/METABOLISM 25, , , ANTI-INFECTIVES 14, , , RESPIRATORY 16, , , MUSCULO-SKELETAL 12, , , GENITO-URINARY 11, , , CYTOSTATICS 7, , , DERMATOLOGICALS 5, , , BLOOD AGENTS 5, , , SENSORY ORGANS 3, , , DIAGNOSTIC AGENTS 2, , , HORMONES 2, , , MISCELLANEOUS 1,516 1 (12) , HOSPITAL SOLUTIONS , PARASITOLOGY : Growth is at Constant Exchange Sales figures in these tables cover direct and indirect pharmaceutical channel purchases (pharmacies plus hospital in Japan and mail order in the USA) from pharmaceutical wholesalers and manufacturers in 13 key global markets. Figures include prescription and certain over-the-counter data, and represent manufacturer prices. These countries account for over two thirds of the world market. These figures are taken from the monthly pharmaceutical audit conducted by IMS Health, the leading provider of healthcare information worldwide and cover the 12 month period from December 2003 through to November Sales for Argentina and Brazil are presented in US dollars only. The decision for the conversion to US dollars was due to excessive inflation and subsequent devaluations leading to both local currency and exchange rates exceeding the field sizes available for them on IMS databases. The selected regions are broken out by country. Each area is also shown in terms of broad therapeutic category. All sales values are shown in millions of dollars at prevailing exchange rates. In order to remove the effects of fluctuating exchange rates, growth rates are calculated net of exchange, in other words, growth figures are shown at local currency level or constant exchange except for the majority of the Latin America countries exclusive of Mexico, Chile, Colombia and Peru. In Argentina and Brazil sales are recorded in US dollars in Mexico local currency. The unique system in Japan reduces the importance of the pharmacy in the distribution chain - sales reported include hospital data. In other countries sales monitored are limited to retail pharmacy only and do not include hospital data. In the USA our survey includes sales through mail order channels. Operating in more than 100 countries, IMS Health is the world's leading provider of information solutions to the pharmaceutical and healthcare industries. With $1.4 billion in 2003 revenue and 50 years of industry experience, IMS Health offers leading-edge business intelligence products and services that are integral to clients day-to-day operations. These include marketing effectiveness solutions for prescription and over-the-counter pharmaceutical products; sales optimisation solutions to increase pharmaceutical sales force productivity; and consulting and customised services that turn information into actionable insights.

5 IMS Retail Drug Monitor Hot Topics Commenting on the key stories January 13th 2005 COMPARED WITH WHAT? In "Outside the Comfort Zone" published in European Pharmaceutical Executive, January/February 2005, Sarah Rickwood outlines the crucial role that benchmarking can play in achieving this goal. The nearer a company approaches a new brand launch, the greater the need for answers to questions such as "are we on track" "have we done the right things to prepare", "how are we doing against our competitors" and most crucially, "how will we know when everything is going right". Those companies that can address these questions with speed and authority across their organization will have coordinated effective launch communications processes, bringing together the different countries, functions and players in the launch process at a time when they are most needed. For further information in this area, please contact: Gail Nielen, Director External Communications: gnielen@uk.imshealth.com Any use of this should be sourced to IMS Health, IMS Retail Drug Monitor.